SYK and psoriasis: Thus, pharmacological targeting of Syk could be a useful tool to suppress overproduction of IFN-I in autoimmune diseases such as systemic lupus erythematosus and psoriasis, where pDCs play a critical role during initiation of the disease and are an attractive therapeutic target [4, 5].